Abstract:
Provided are methods for treating alcohol use disorders using opioid receptor antagonists. In some embodiments, the presently disclosed methods include assaying nucleic acid from a subject regarding the subject's genotype with respect to the COMT and OPRM1 genes and administering or not administering an opioid receptor antagonist to the subject on the basis therefore. Also provided are methods for detecting susceptibility to an opioid receptor antagonist therapy for disorders associated with opioid receptor activity and methods for identifying and treating human subjects having susceptibility to opioid receptor antagonist therapies for disorders associated with opioid receptor activity.
Abstract:
Embodiments disclosed herein relate to methods and apparatus for cell block preparation of cytology specimens. Specific embodiments relate to methods and apparatus for formal-in fixed paraffin embedded cell block preparation of cytology specimens.
Abstract:
A compound, or a pharmaceutically acceptable salt thereof, having a structure of wherein Z is aryl or substituted aryl, heteroaryl, or substituted heteroaryl; X is —S—, —S(O)—, or S(O)2—; R20 and R21 are each independently H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, or halogenated alkyl; one of R22, R23, and R24 is —O— and the others of R22, R23 and R24 are independently —CH2—, or —C(R13)— wherein R13 is alkyl, alkenyl, alkynyl, trialkylsilyl group, or —(CH2)mOR15, wherein R15 is alkyl or an aryl and m is an integer in the range of 1 to 10; and R25 is H, alkyl, substituted alkyl, halogen, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, C1-C3 alkoxy, aryloxy, or —(CH2)qOR17, wherein R17 is alkyl an aryl and q is an integer in the range of 1 to 10.
Abstract:
Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of degenerative diseases and disorders.
Abstract:
One aspect of the present disclosure relates to a system that can determine a kurtosis diffusion orientation distribution function (dODF) that can, for example, be used with diffusional kurtosis imaging fiber tractography (DKI-FT). The system can include a non-transitory memory storing computer-executable instructions and a processor that executes the computer-executable instructions to perform the following operations. Diffusion magnetic resonance imaging (dMRI) data can be received. Based on the dMRI data, a diffusion tensor (DT) and a diffusional kurtosis tensor (DKT) can be determined. A kurtosis dODF can be determined for the dMRI data based on the DT and the DKT. The kurtosis dODF extends a Gaussian approximation of the DT to include non-Gaussian corrections of the DKT.
Abstract:
Provided are peptides that can inhibit collagen synthesis, processing and/or secretion from scar forming cells or fibroblasts. Also provided are methods for using the peptides to produce an anti-fibrotic, anti-scarring, anti-inflammatory, and/or pro-regenerative effect, e.g., on an injured or diseased tissue.
Abstract:
An expandable vertebral body device, system, instrument, and methods of assembly and using the device, system, and instrument are disclosed. The vertebral body device includes a body with a first end and a second end, a first rotating member rotatably coupled to the first end, a second rotating member rotatably coupled to the second end, a first extension member moveably coupled to the first end, and a second extension member moveably coupled to the second end. The expandable cage system comprises a vertebral body device and an insertion instrument. Methods for assembling and using the vertebral body device and instrument are also disclosed.
Abstract:
Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of degenerative diseases and disorders.
Abstract:
The present invention provides for methods of producing human monoclonal antibodies to human nucleolin, cells producing such antibodies, and the antibodies themselves. Also provided are methods of using the antibodies in diagnosing and treating malignant and non-malignant diseases wherein cells that express nucleolin on the cell surface contribute to the pathophysiology of the disease.